When hearts fail so does skeletal muscle: Breaking a vicious cycle

Circulation Research

Volumn 98, Issue 12, 2006, Pages 1456-1458

  Biesiadecki, Brandon J ^a   Solaro, R John ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Animal models of human disease; Congestive heart failure; Heart failure; Hypertrophy

Indexed keywords

ALPHA ACTIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ION; CARVEDILOL; PHOSPHATE; REACTIVE OXYGEN METABOLITE; TROPOMYOSIN; TROPONIN I; TROPONIN T; CALCIUM;

ACIDOSIS; CALCIUM CELL LEVEL; EDITORIAL; FATIGUE; HEART FAILURE; HEART MUSCLE; HYPOXIA; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; SARCOMERE; SKELETAL MUSCLE; ANIMAL; FORWARD HEART FAILURE; HUMAN; METABOLISM; MUSCLE CONTRACTION; NOTE; PATHOPHYSIOLOGY;

ANIMALS; CALCIUM; CARDIAC OUTPUT, LOW; HUMANS; MUSCLE CONTRACTION; MUSCLE, SKELETAL; SARCOMERES;

EID: 33746500849     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000231259.29646.74     Document Type: Editorial

References (22)

1. Drexler H, Coats AJ. Explaining fatigue in congestive heart failure. Ann Rev Med. 1996;47:241-246.
2. Dalla Libera L, Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimeric view of inflammation? Curr Opin Clin Nutr Metab Care. 2004;7:435-441.
3. 2+ handling in skeletal muscle during fatigue. Circ Res. 2006;98:1514-1519.
4. 2+-transients in isolated bundles of skeletal muscle fibers from rats with chronic heart failure. Circ Res. 1993;73:405-412.
5. de Tombe PP, Solaro RJ. Integration of cardiac myofilament activity and regulation with pathways signaling hypertrophy and failure. Ann Biomed Eng. 2000;28:991-1001.
6. Marston SB, Redwood CS. Modulation of thin filament activation by breakdown or isoform switching of thin filament proteins: physiological and pathological implications. Circ Res. 2003;93:1170-1178.
7. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, Berry CE, Vandegaer KM, Li D, Hare JM. Xanthine oxido-reductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006;98:271-279.
8. Tardiff JC. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev. 2005;10:237-248.
9. Supinski GS, Calahan LA. Diaphragmatic free radical generation increases in an animal model of heart failure. J Appl Physiol. 2005;99:1078-1084.
10. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. In press.
11. Yu Z-B, Xhang L-F, Jin J-P. A proteolytic NH2-terminal truncation of cardiac troponin I that is up-regulated in simulated microgravity. J Biol Chem. 2001;276:15753-15760.
12. Communal C, Sumandea M, deTombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci. 2002;99:6252-6256.
13. McDonough JL, Arrell DK, VanEyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res. 1999;84:9-20.
14. Brotto MP, VanLeyen SA, Brotto LS, Jin J-P, Nosek CM, Nosek TM. Hypoxia/fatigue-induced degradation of troponin I and troponin C: new insights into physiologic muscle fatigue. Eur J Physiol. 2001;442:738-744.
15. Simpson JA, VanEyk JE, Iscoe S. Hypoxemia-induced modification of troponin I and T in canine diaphragm. J Appl Physiol. 2000;88:753-760.
16. Canton M, Skyschally A, Menabo R, Boengler K, Gres P, Schulz R, Haude M, Erbel R, Di Lisa F, Heusch G. Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur Heart J 2006;2006;27:875-881.
17. Dalla Libera L, Ravara B, Gobbo V, Danieli Betto D, Germinario E, Angelini A, Vescovo G. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol. 2005;38:803-807.
18. Heeley DH. Investigation of the effects of phosphorylation of rabbit striated muscle αα-tropomyosin and rabbit skeletal muscle troponin T. Eur J Biochem. 1994;221:129-137.
19. Chen F, Ogut O. Decline of contractility during ischemia-reperfusion injury: actin glutathionylation and its effect on allosteric interaction with tropomyosin. Am J Physiol Cell Physiol. 2006;290:C719-C727.
20. Godt RE, Nosek TM. Changes of intracellular milieu with fatigue or hypoxia depress contraction of skinned rabbit skeletal and cardiac muscle. J Physiol. 1989;412:155-180.
21. Solaro RJ, Varghese J, Marian AJ, Chandra M. Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol. 2002;97:I102-I110.
22. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magrino C. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 2000;101:122-124.